hVIVO (LON:HVO) Shares Down 46.3% - Here's What Happened

Shares of hVIVO plc (LON:HVO - Get Free Report) traded down 46.3% during trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares changed hands during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Ratings Changes

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The business's 50 day moving average is GBX 15.92 and its 200 day moving average is GBX 17.70. The stock has a market cap of £73.59 million, a price-to-earnings ratio of 4.29 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($705,491.02). Corporate insiders own 14.03% of the company's stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.